Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. PureTech Share Price
  4. PureTech Share Regulatory News
  5. Transaction in Own Shares

Pin to quick picksPureTech Regulatory News (PRTC)

PureTech Information

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 221.00
Bid: 221.00
Ask: 222.50
Change: -1.50 (-0.67%)
Spread: 1.50 (0.679%)
Open: 222.50
High: 225.00
Low: 219.00
Prev. Close: 222.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

27 Nov 2023 07:00

RNS Number : 6659U
PureTech Health PLC
27 November 2023
 

27 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

24 November 2023

Number of ordinary shares purchased:

32,582

Highest price paid per share:

165.20p

Lowest price paid per share:

162.20p

Volume weighted average price paid per share:

163.39p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,588,788 ordinary shares in treasury and has 272,879,371 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 272,879,371 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

24/11/2023

08:15:26

507

165.2

XLON

00379762139TRLO0.1.1

24/11/2023

09:17:37

118

163.8

TRQX

00379770575TRLO0.1.1

24/11/2023

09:17:37

1014

164.2

CHIX

00379770574TRLO0.1.1

24/11/2023

09:17:37

507

164.2

XLON

00379770577TRLO0.1.1

24/11/2023

09:17:37

507

164.2

XLON

00379770576TRLO0.1.1

24/11/2023

10:40:42

240

164.2

CHIX

00379781661TRLO0.1.1

24/11/2023

10:40:59

363

164.2

XLON

00379781675TRLO0.1.1

24/11/2023

12:12:22

620

163

XLON

00379791766TRLO0.1.1

24/11/2023

12:12:22

49

163

XLON

00379791768TRLO0.1.1

24/11/2023

12:12:22

49

163

XLON

00379791767TRLO0.1.1

24/11/2023

12:20:28

3989

163

XLON

00379792505TRLO0.1.1

24/11/2023

12:20:28

507

162.8

XLON

00379792506TRLO0.1.1

24/11/2023

12:20:28

774

164

CHIX

00379792508TRLO0.1.1

24/11/2023

12:20:30

248

162.4

BATE

00379792521TRLO0.1.1

24/11/2023

12:20:30

259

162.4

BATE

00379792520TRLO0.1.1

24/11/2023

12:20:30

507

162.4

BATE

00379792522TRLO0.1.1

24/11/2023

12:20:30

507

162.4

CHIX

00379792523TRLO0.1.1

24/11/2023

12:20:30

63

162.4

CHIX

00379792524TRLO0.1.1

24/11/2023

12:20:30

273

162.4

CHIX

00379792525TRLO0.1.1

24/11/2023

12:20:35

118

162.2

TRQX

00379792534TRLO0.1.1

24/11/2023

12:20:35

69

162.2

TRQX

00379792535TRLO0.1.1

24/11/2023

12:20:35

49

162.2

TRQX

00379792536TRLO0.1.1

24/11/2023

13:16:39

12

163.8

XLON

00379797005TRLO0.1.1

24/11/2023

13:16:40

214

163.8

XLON

00379797006TRLO0.1.1

24/11/2023

13:16:40

7

163.8

XLON

00379797007TRLO0.1.1

24/11/2023

13:16:40

340

163.8

XLON

00379797008TRLO0.1.1

24/11/2023

13:16:40

264

163.8

XLON

00379797009TRLO0.1.1

24/11/2023

13:16:40

177

163.8

XLON

00379797010TRLO0.1.1

24/11/2023

13:18:45

350

164

XLON

00379797229TRLO0.1.1

24/11/2023

13:18:45

3150

164.2

XLON

00379797230TRLO0.1.1

24/11/2023

14:05:53

1202

163.2

XLON

00379801746TRLO0.1.1

24/11/2023

14:07:28

910

163

XLON

00379801878TRLO0.1.1

24/11/2023

14:42:06

635

163.2

XLON

00379814440TRLO0.1.1

24/11/2023

14:42:06

886

163.2

XLON

00379814439TRLO0.1.1

24/11/2023

14:42:07

457

163

CHIX

00379814446TRLO0.1.1

24/11/2023

14:42:07

50

163

CHIX

00379814445TRLO0.1.1

24/11/2023

14:42:07

369

163

CHIX

00379814447TRLO0.1.1

24/11/2023

14:42:07

177

163

AQXE

00379814448TRLO0.1.1

24/11/2023

14:42:07

138

163

CHIX

00379814449TRLO0.1.1

24/11/2023

14:50:11

507

162.6

BATE

00379818122TRLO0.1.1

24/11/2023

14:50:11

507

162.6

BATE

00379818123TRLO0.1.1

24/11/2023

15:16:17

1014

162.6

XLON

00379827444TRLO0.1.1

24/11/2023

15:41:32

119

163.4

XLON

00379835751TRLO0.1.1

24/11/2023

15:41:33

60

163.4

XLON

00379835752TRLO0.1.1

24/11/2023

15:41:33

1

163.4

XLON

00379835753TRLO0.1.1

24/11/2023

15:51:48

507

163.4

BATE

00379838757TRLO0.1.1

24/11/2023

15:51:48

234

163.4

CHIX

00379838758TRLO0.1.1

24/11/2023

15:51:48

1521

163.6

XLON

00379838759TRLO0.1.1

24/11/2023

15:51:48

273

163.4

CHIX

00379838760TRLO0.1.1

24/11/2023

15:51:48

118

163

TRQX

00379838761TRLO0.1.1

24/11/2023

15:51:52

350

164

AQXE

00379838775TRLO0.1.1

24/11/2023

15:51:52

531

164

AQXE

00379838776TRLO0.1.1

24/11/2023

16:10:31

639

163

XLON

00379844964TRLO0.1.1

24/11/2023

16:18:46

882

163

XLON

00379847596TRLO0.1.1

24/11/2023

16:29:34

1747

163.4

CHIX

00379851063TRLO0.1.1

24/11/2023

16:29:35

13

163.4

CHIX

00379851070TRLO0.1.1

24/11/2023

16:29:35

42

163.4

CHIX

00379851077TRLO0.1.1

24/11/2023

16:29:41

1693

163.4

CHIX

00379851146TRLO0.1.1

24/11/2023

16:29:42

225

163.4

CHIX

00379851167TRLO0.1.1

24/11/2023

16:29:43

246

162.8

XLON

00379851187TRLO0.1.1

24/11/2023

16:29:51

678

164

AQXE

00379851256TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFFFIFLILSFIV
91011121314151617
Date   Source Headline
26th Apr 20211:05 pmRNSGelesis Appoints Procter & Gamble Veteran to BOD
15th Apr 20217:00 amRNSFinal Results
12th Apr 202112:00 pmRNSPRTC Presents Data for LYT-210 IO Program at AACR
7th Apr 202112:00 pmRNSPureTech to Present at Two Investor Conferences
7th Apr 202110:15 amRNSAkili Collab to Study Long COVID-Related Brain Fog
26th Mar 202112:02 pmRNSAkili Data Published in Nature Digital Medicine
24th Mar 20217:00 amRNSHolding(s) in Company
18th Mar 20217:00 amRNSDirectorate Change
15th Mar 20217:00 amRNSNotice of Results
3rd Mar 202112:00 pmRNSPRTC Presents at Barclays Healthcare Conference
2nd Mar 20211:01 pmRNSKaruna Prices Approximately $250M Public Offering
25th Feb 20212:00 pmRNSPRTC Publishes Lymphatic Targeting Study for Glyph
25th Feb 20217:00 amRNSKaruna data in New England Journal of Medicine
18th Feb 202112:00 pmRNSPRTC Presents at SVB Leerink Healthcare Conference
10th Feb 20217:05 amRNSVor Closes Over $200M Initial Public Offering
10th Feb 20217:00 amRNSPRTC Receives $118M from Founded Entity Shares
8th Feb 202112:00 pmRNSVedanta Adds Biotech Finance and IR Expert as CFO
5th Feb 202111:46 amRNSPureTech Founded Entity Vor Lists on Nasdaq
5th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSTotal Voting Rights
29th Jan 20217:00 amRNSPureTech Appoints Bharatt Chowrira to BOD
18th Jan 20217:00 amRNSVor Files IPO Registration Statement on Nasdaq
14th Jan 202112:05 pmRNSVor Announces FDA Acceptance of IND Application
14th Jan 202111:50 amRNSAesthetic Med & Dermatology Veterans Join Follica
12th Jan 202111:50 amRNSVedanta Receives $25M Investment from Pfizer Inc
5th Jan 20217:00 amRNSPRTC Appoints Biotech Analyst & Senior Exec as CFO
4th Jan 20217:00 amRNSTotal Voting Rights
21st Dec 202012:00 pmRNSPureTech to Present at JPM and Other Conferences
21st Dec 20207:00 amRNSDirector/PDMR Shareholding
11th Dec 202012:00 pmRNSPRTC Starts LYT-200 Clinical Trial in Solid Tumors
11th Dec 20207:00 amRNSHolding(s) in Company
10th Dec 202012:00 pmRNSLYT-100 Advances to Phase 2a Study in Lymphedema
9th Dec 202012:00 pmRNSFollica Female Hair Loss Academic Study Published
3rd Dec 202012:00 pmRNSPureTech Initiates Ph 2 of LYT-100 in Long COVID
1st Dec 20207:00 amRNSTotal Voting Rights
30th Nov 202012:00 pmRNSPureTech to Host Virtual R&D Day for Investors
27th Nov 20204:41 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
27th Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
27th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Nov 202012:00 pmRNSVedanta Appoints Karuna CFO Troy Ignelzi to BOD
23rd Nov 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th Nov 20207:00 amRNSPRTC LYT-100 Shows PK & Tolerability Ph1 POC
16th Nov 20207:00 amRNSPureTech to Present at Three Investor Conferences
13th Nov 20205:05 pmRNSGuidance for Exchanging Ordinary Shares into ADSs
13th Nov 20205:00 pmRNSDirector/PDMR Shareholding
13th Nov 20201:04 pmRNSGelesis Presents New Data at The Liver Meeting
13th Nov 20207:00 amRNSPureTech to Commence Nasdaq Trading on 16 November
91011121314151617

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.